The board of directors at Acorda Therapeutics (ACOR) has docked the pay of CEO Ron Cohen for a series of missteps that hobbled the drug maker last year.

Cohen was due to receive a 2017 bonus of just under $255,000 — about half of his customary bonus — because Acorda only achieved 40 percent of its corporate goals for the year, according to a proxy statement filed Friday.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • When the CEO of a company is not rewarded with a bonus, and is told that if the drug trials are deemed feasible for the use that patients will receive, and hopefully will be successful with the treatment protocol, then that is a significant justification for the pharmaceutical company to only reward the top executive any bonus, based on its efficacy. I hope that this is the way that all pharmaceutical companies reward the individuals who are employed by the companies, and/or removing them from their employment in the company.

Your daily dose of news in health and medicine

Privacy Policy